Kairos Pharma Files 8-K: Other Events & Exhibits
Ticker: KAPA · Form: 8-K · Filed: Mar 20, 2025 · CIK: 1962011
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Kairos Pharma filed an 8-K on 3/20/25 for 'Other Events' and exhibits. No major news yet.
AI Summary
On March 20, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events or financial details disclosed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Los Angeles, California.
Why It Matters
This 8-K filing indicates that Kairos Pharma, Ltd. has submitted required regulatory documentation, though the specific details of the 'Other Events' or 'Financial Statements and Exhibits' are not elaborated upon in this excerpt.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and exhibits, with no disclosed material changes or negative news.
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- March 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Kairos Pharma, Ltd. in this 8-K filing?
The provided text for the 8-K filing does not specify the details of the 'Other Events'.
What is the significance of the 'Financial Statements and Exhibits' being filed?
The filing indicates that financial statements and exhibits are being submitted, but the content or nature of these documents is not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 20, 2025.
Where are Kairos Pharma, Ltd.'s principal executive offices located?
Kairos Pharma, Ltd.'s principal executive offices are located at 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding Kairos Pharma, LTD. (KAPA).